Form 4: Amneal Pharmaceuticals' President & Co-CEO, Chirag K. Patel, Reports Stock Unit Grants

Chirag K. Patel, President & Co-CEO of Amneal Pharmaceuticals, reports the acquisition of restricted stock units and performance-based restricted stock units.

Summary

• Chirag K. Patel, President & Co-CEO of Amneal Pharmaceuticals, filed a Form 4 on March 5, 2024, reporting changes in beneficial ownership.
• The report details the acquisition of 370,370 restricted stock units and 1,333,334 performance-based restricted stock units on March 4, 2024.
• The restricted stock units vest in four equal annual installments starting March 4, 2025.
• The performance-based restricted stock units vest on February 28, 2027, based on Amneal's Class A Common Stock achieving certain average closing price targets, with the number of shares varying from 0% to 200% of the target.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of restricted stock units and performance-based restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule for the restricted stock units encourages long-term commitment from the executive.
• The performance-based restricted stock units incentivize the executive to drive stock price appreciation.

Risks

• The value of the restricted stock units and performance-based restricted stock units is dependent on the future performance of Amneal Pharmaceuticals' stock.
• The performance-based restricted stock units may not vest if the stock price targets are not met.

Future Outlook

The vesting of the performance-based restricted stock units is contingent on the company's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period, ending February 28, 2027.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation. The specific terms of the grants, such as vesting schedules and performance metrics, vary from company to company.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among publicly traded pharmaceutical companies.
• Companies like Teva Pharmaceutical Industries and Mylan (now Viatris) also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these grants are typically aligned with long-term shareholder value creation, similar to Amneal's approach.

Stakeholder Impact

• The stock grants align management's interests with those of shareholders, potentially leading to increased shareholder value.
• The grants may motivate the executive to improve company performance, benefiting employees and other stakeholders.

Key Dates